

S2 Data. Supplemental figures A-G.




Figure A. Geometric mean titer (GMT) ID80 at enrollment visit and 95% CI by enrollment group, severity, medical history, and days since COVID-19 onset in Americas.




Figure B. Estimated age effect on nAb log-titers stratifying by COVID-19 severity adjusting for COVID-19 severity, medical history, other demographics, and days since SARS-CoV-2 diagnosis using generalized additive model.




Figure C. Geometric mean titer (GMT) of nAb ID50 (A) and ID80 (B) titer at the enrollment visit in Americas. White asterisks denote groups with fewer than 10 participants.




Figure D. Estimated days since SARS-CoV-2 diagnosis (days) effect on nAb log-titers stratifying by COVID-19 severity adjusting for COVID-19 severity, medical history, and demographics using generalized additive model.




Figure E. Estimated BMI effect on nAb log-titers stratifying by COVID-19 severity adjusting for COVID-19 severity, medical history, other demographics, and days since SARS-CoV-2 diagnosis using generalized additive model.






Figure F. Geometric mean titer (GMT) at enrollment visit and 95% CI by enrollment group, severity, medical history, and days since SARS-CoV-2 diagnosis in USA and Peru. A. Peru, ID50. B. Peru, ID80. C. US, ID50. D. US, ID80.

US

C



D






Figure G. NAb titers by prolonged viral shedding status and COVID-19 severity.